The Woodlands, Texas – April 30, 2010
VGXI, Inc., a leading provider of DNA plasmid manufacturing and development services, announced today that Henry Hebel, VGXI’s Chief Operating Officer, participated in a vidcast interview at INTERPHEX New York discussing pandemic preparedness and universal flu vaccine development. The interview took place in front of a live audience and also was videotaped for presentation through INTERPHEX’s web sites. A recording of the interview can be viewed here.
About INTERPHEX New York
INTERPHEX New York is a member of the global family of INTERPHEX events. INTERPHEX
USA is the world’s most trusted source for leading-edge technology, education, and sourcing of
the products and services that drive scientific innovation for Life Sciences manufacturing.
INTERPHEX New York is produced by Reed Exhibitions, delivering influential leaders in life
sciences through unique combinations of conference, exhibition, workshops, partnering
opportunities, and networking events. Reed Exhibitions manages more than 450 trade shows
annually worldwide and is a member of the Reed Elsevier Group plc, a world-leading provider of
information-driven services and solutions. For information, visit www.interphex.com.
About VGXI Inc.
VGXI Inc. is a leading provider of DNA plasmid manufacturing and development services for DNA vaccine and gene therapy research. The Company has an outstanding track record of success in manufacturing plasmid products under cGMP conditions for client companies’ clinical studies in the US and Europe, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. The recently announced research and pre-clinical production services extend the range of high-quality, research grade materials utilizing the same efficient service. This rapid turnaround program provides consistent materials to build a reliable pre-clinical dataset. For information, visit 22.214.171.124/~vgxiico2
Factors That May Affect Future Results
Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations.Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.